Vertex Pharmaceuticals (VRTX) Common Equity (2009 - 2026)

Vertex Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $19.4 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 17.37% year-over-year to $19.4 billion in Q1 2026; TTM through Mar 2026 was $19.4 billion, a 17.37% increase from a year earlier, with the FY2025 full-year figure at $18.7 billion, up 13.75% from the prior year.
• Common Equity improved to $19.4 billion in Q1 2026 per VRTX's latest filing, from $18.7 billion in the prior quarter.
• Across five years, Common Equity topped out at $19.4 billion in Q1 2026 and bottomed at $10.9 billion in Q1 2022.
• The 5-year median for Common Equity is $16.4 billion (2024), against an average of $15.8 billion.
• Across the five-year window, Common Equity soared 37.75% in 2022 and slipped 11.05% in 2025, its largest moves.
• Year by year, Common Equity stood at $13.9 billion in 2022, then advanced by 26.36% to $17.6 billion in 2023, then declined by 6.66% to $16.4 billion in 2024, then gained by 13.75% to $18.7 billion in 2025, then grew by 3.73% to $19.4 billion in 2026.
• Per Business Quant, the three latest VRTX Common Equity figures stand at $19.4 billion (Q1 2026), $18.7 billion (Q4 2025), and $17.3 billion (Q3 2025).